France Seeks Stronger Cost-Effectiveness Tools To Lower Drug Prices, But Pan-European Bulk Buying May Come First
Executive Summary
France’s drugs assessment agency wants simpler, stronger rules to evaluate the cost-effectiveness of new drugs. But changes to the country’s complex reimbursement system may be too slow to address immediate budget concerns, making pan-European bulk buying appear a more likely near-term solution.